Histopathologic prognosis of thymomas: Another example of medical surrogacy

American Journal of Clinical Pathology

Volumn 134, Issue 5, 2010, Pages 703-705

  Wick, Mark R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; EDITORIAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; THYMOMA; WORLD HEALTH ORGANIZATION; HUMAN; PATHOLOGY;

HUMANS; PROGNOSIS; THYMOMA; THYMUS NEOPLASMS;

EID: 78049499232     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPF4KT2PEXZUSD     Document Type: Editorial

References (30)

1. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27. (Pubitemid 40066168)
2. Bohn OL, Nasir I, Brufsky A, et al. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol. 2009;3:139-146.
3. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62. doi:10.1186/bcr1614. (Pubitemid 44971093)
4. Karlsson E, Delle U, Danielsson A, et al. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer. 2008;8:254. doi:10.1186/1471-2407-8-254.
5. Staaf J, Ringner M, Vallon-Christersson J, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010;28:1813-1820.
6. Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small-cell lung cancer. Thorax. 2001;56:561-566. (Pubitemid 32588536)
7. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10:242-248.
8. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small-cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133:922-934.
9. Murphy LC, Skliris GP, Rowan BG, et al. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J Steroid Biochem Mol Biol. 2009;114:90-95.
10. Nadji M. Quantitative immunohistochemistry of estrogen receptors in breast cancer: "much ado about nothing!" Appl Immunohistochem Mol Morphol. 2008;16:105-107.
11. Charpin C, Secq V, Giusiano S, et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer. 2009;124:2124-2134.
12. Dacic S, Yousem SA. Molecular testing in lung carcinoma: quo vadis [editorial]? Am J Clin Pathol. 2010;134:7-9.
13. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978;5:428-433.
14. Pertschuk LP, Tobin EH, Gaetjens E, et al. Histochemical assay of estrogen and progesterone receptors in breast cancer: correlation with biochemical assays and patient response to endocrine therapies. Cancer. 1980;46(12 suppl):2896-2901.
15. Seymour L, Meyer K, Esser J, et al. Estimation of PR and ER by immunocytochemistry in breast cancer: comparison with radioligand binding methods. Am J Clin Pathol. 1990;94(suppl):S35-S40.
16. Moran CA, Kalhor N, Suster S. Invasive spindle-cell thymomas (WHO type A): clinicopathologic correlation of 41 cases. Am J Clin Pathol. 2010;134:793-798.
17. Kim BK, Cho BC, Choi HJ, et al. A single institutional experience of surgically-resected thymic epithelial tumors of 10 years: clinical outcomes and clinicopathologic features. Oncol Rep. 2008;19:1525-1531.
18. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg. 2010;89:245-252.
19. Moran CA, Suster S. The World Health Organization (WHO) histologic classification of thymomas: a reanalysis. Curr Treat Options Oncol. 2008;9:288-299.
20. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328-2334.
21. Wick MR. Prognostic factors for thymic epithelial neoplasms, with emphasis on tumor staging. Hematol Oncol Clin North Am. 2008;22:527-542.
22. Rosai J. World Health Organization International Histological Classification of Tumours: Histological Typing of Tumors of the Thymus. 2nd ed. Berlin, Germany: Springer; 1999.
23. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of. 200 thymoma cases from China. Cancer. 2002;95:420-429. (Pubitemid 34787609)
24. Nakagawa K, Asamura H, Matsuno Y, et al. Thymoma. a clinicopathological study based on the new World Health Organization classification. J Thorac Cardiovasc Surg. 2003;126:1134-1140. (Pubitemid 37305702)
25. Marchevsky AM, Gupta R, McKenna RJ, et al. Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer. 2008;112:2780-2788.
26. Kim HK, Choi YS, Kim J, et al. Type B thymoma: is prognosis predicted only by World Health Organization classification? J Thorac Cardiovasc Surg. 2010;139:1431-1435.
27. Bernatz PE, Harrison EG Jr, Claggett OT. Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg. 1961;42:424-444.
28. Lewis JE, Wick MR, Scheithauer BW, et al. Thymoma: a clinicopathologic review. Cancer. 1987;60:2727-2743.
29. Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma: a novel conceptual approach to the classification of neoplasms of thymic epithelium. Am J Clin Pathol. 1999;111:826-833.
30. Gupta R, Marchevsky AM, McKenna RJ, et al. Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med. 2008;132:926-930.